To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

View sample alert

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Scheduled Event - 2 May 2024, 11 a.m.
View Source
Lords - Oral questions - Main Chamber
Assessment of NHS England London stating that “anyone with ovaries can get ovarian cancer” in a social media post rather than referring to "women"
MP: Baroness Hayter of Kentish Town
Commons Chamber
Oral Answers to Questions - Tue 23 Apr 2024
Department of Health and Social Care

Mentions:
1: Theresa Villiers (Con - Chipping Barnet) Will the Secretary of State support Breast Cancer Now’s campaign to improve the uptake of breast cancer - Speech Link
2: Victoria Atkins (Con - Louth and Horncastle) Members on both sides of the House, for further research into lobular breast cancer, because although - Speech Link
3: Ruth Cadbury (Lab - Brentford and Isleworth) At my last surgery, a young woman told me that, thanks to the delay in her GP diagnosing her ovarian - Speech Link

Commons Chamber
Hospice Funding - Mon 22 Apr 2024
Department of Health and Social Care

Mentions:
1: Sally-Ann Hart (Con - Hastings and Rye) Both my parents died of cancer, and I will always be grateful for the amazing care that they received - Speech Link
2: Jim Shannon (DUP - Strangford) We have a Marie Curie hospice in Belfast that gives excellent care to those who have cancer. - Speech Link
3: Peter Gibson (Con - Darlington) It has received some non-recurrent funding through the cancer charities relief fund, but may be unable - Speech Link
4: Jim Shannon (DUP - Strangford) She was not feeling well, and the doctor told her that she had only four weeks to live—she had cancer - Speech Link
5: Andrew Gwynne (Lab - Denton and Reddish) It was 30 years ago that I lost my mum to ovarian cancer—I was 19. - Speech Link

Departmental Publication (Policy and Engagement)
Department for Business and Trade

Apr. 18 2024

Source Page: The Smart Data Roadmap: action the government is taking in 2024 to 2025
Document: (PDF)

Found: A recent study, funded by Cancer Research UK found that analysis of loyalty card data , from two UK

Scottish Government Publication (FOI/EIR release)
Population Health Directorate

Apr. 16 2024

Source Page: CA125 blood test for Ovarian Cancer: FOI release
Document: CA125 blood test for Ovarian Cancer: FOI release (webpage)

Found: CA125 blood test for Ovarian Cancer: FOI release

Departmental Publication (Transparency)
Home Office

Apr. 12 2024

Source Page: Non-technical summaries granted in 2024
Document: Non-technical summaries: projects granted in 2024, January to March (PDF)

Found: Studying novel treatments for ovarian Cancer 669 80.

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Apr. 09 2024

Source Page: MHRA FOI performance data
Document: (Excel)

Found: you be able to advise whether MHRA are looking to approve mirvetuximab for use in platinum resistant ovarian

Non-Departmental Publication (Guidance and Regulation)
Medicines and Healthcare products Regulatory Agency

Apr. 04 2024

Source Page: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines
Document: M3(R2) – Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (PDF)

Found: Pharmaceuticals under development for indications i n life-threatening or serious diseases (e.g., advanced cancer

Non-Departmental Publication (Guidance and Regulation)
Medicines and Healthcare products Regulatory Agency

Apr. 04 2024

Source Page: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines
Document: S5(R3) – Revision of S5 Guidelines on Detection of Toxicity to Reproduction for Human Pharmaceuticals (PDF)

Found: Comparison of the intraperitoneal and intravenous routes of cisplatin administration in an advanced ovarian

Written Question
Ovarian Cancer: Diagnosis
Tuesday 2nd April 2024

Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether her Department plans to shorten the diagnostic pathway for ovarian cancer by allowing the CA125 blood test and ultrasound to be undertaken at the same time.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Department is supporting NHS England in developing Best Practice Timed pathways, to support the ongoing improvement effort to shorten diagnosis pathways, reduce variation, improve patient experience of care, and meet the Faster Diagnosis Standard. This standard ensures patients are told they have cancer, or that cancer is ruled out, within 28 days of urgent cancer referral from general practice or screening service.

In March 2023, NHS England published guidance for local health and care systems to implement a timed gynaecological cancer diagnostic pathway, including for ovarian cancer. The gynaecological pathway ensures that at day zero, when presenting with symptoms, an ultrasound and a minimum data set is obtained, which includes a full blood count. For patients with suspected ovarian cancer, the minimum dataset should also include tumour marker CA125, with confirmation of suspicious features of ovarian cancer on ultrasound.

The guidance further ensures that patients with persistent abdominal symptoms, raised CA125, and a normal pelvic scan should be referred through the non-specific symptoms rapid diagnostic centre pathway. Women over 50 years old with elevated CA125 and palpable mass or ascites, or both, or with a previous ultrasound with risk of malignancy, should be referred straight to a computed tomography scan.